| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.9 | 3.4 |
| Gross profit | 1.5 | 3.1 |
| Profit before tax | -4.7 | -1.5 |
| Net income | -4.7 | -2.1 |
| EPS (diluted, $ a share) | $-0.07 | $-0.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -44.0% |
|---|---|
| Gross margin | 80.5% |
| Operating margin | -19.5% |
10-Q filed with the SEC, OTC: EMMA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Emmaus Life Sciences, Inc.: key numbers
- Share price
- $0.0320Close, Nov 20
- Market cap
- $2.25M
- Shares outstanding
- 70.19MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Emmaus Life Sciences, Inc.
All →Emmaus Life Sciences Financial Results
Emmaus Life Sciences reported Q3 2026 net revenues of $1.9 million, a decline from $3.4 million in the prior year period, primarily due to a 44% decrease in U.S. revenues following a licensing agreement with NeoImmuneTech. The company realized a net loss of $4.7 million for the quarter, impacted by lower direct sales of Endari and an increase in other expenses related to the fair value of conversion features.
- Term
- Q3 2026
“Our global net revenues declined for the three months ended September 30, 2026 as compared to the same period in 2025 primarily driven by a 44% decrease in U.S. net revenues as our licensing agreement with NeoImmuneTech Inc. (NIT), became effective on May 15, 2026.”
Willis Lee, Chairman and Chief Executive Officer
“The decline was partially offset by a related reduction in our operating expenses. Management believes that the conflict in the Midde East also adversely affected net revenues in the region,”
Willis Lee, Chairman and Chief Executive Officer